GlassScriptPhysician profile
Joseph C Portera
NPI 1821088410
$2,884.92
in general payments reported to CMS, 2019-2025
34 companies · $450 in 2025
The $450 reported for 2025 was more than what a typical Gynecology provider received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $311 · 2020: $133 · 2021: $110 · 2022: $807 · 2023: $546 · 2024: $528 · 2025: $450.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,524.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,524.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $636.17 | 2019-2025 | Veozah, Myrbetriq |
| Sumitomo Pharma America, INC. | $372.35 | 2023-2025 | Gemtesa, Myfembree |
| Boston Scientific Corporation | $326.30 | 2022-2025 | Advantage System, Solyx Sis System, General - Female Sui |
| Urovant Sciences INC | $243.62 | 2021-2022 | |
| Abbvie INC. | $209.28 | 2019-2023 | |
| Aspira Women'S Health INC | $156.98 | 2022 | |
| Pfizer INC. | $147.94 | 2019-2025 | |
| Allergan, INC. | $102.84 | 2019-2020 | |
| Therapeuticsmd, INC. | $101.80 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $60.04 | 2022 | |
| Coloplast Corp | $59.27 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.32 | 2023-2025 | |
| Avion Pharmaceuticals | $38.22 | 2019-2022 | |
| Myovant Sciences INC. | $36.95 | 2022 | |
| Baxter Healthcare | $31.01 | 2025 | Seprafilm |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $26.76 | 2020-2022 | |
| Lundbeck LLC | $22.71 | 2023 | Vyepti |
| Millicent US INC | $22.03 | 2025 | Intrarosa |
| Organon LLC | $20.95 | 2025 | Nexplanon |
| Shield Therapeutics INC | $20.82 | 2023 | Accrufer |
| Sage Therapeutics, LLC | $19.36 | 2025 | Zurzuvae |
| Scynexis, INC. | $17.70 | 2022 | |
| Exeltis, USA INC. | $16.69 | 2020 | |
| Gynesonics, INC. | $15.34 | 2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Exact Sciences Corporation | $15.21 | 2023 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $14.71 | 2022 | |
| Provepharm INC. | $14.62 | 2025 | Bludigo |
| Ferring Pharmaceuticals INC. | $14.49 | 2019 | |
| Amgen INC. | $14.20 | 2020 | |
| Minerva Surgical, INC | $13.66 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $13.57 | 2021 | |
| Medtronic, INC. | $13.57 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.83 | 2019 | |
| Mylan Pharmaceuticals INC. | $11.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Portera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.